ATE429252T1 - Adeno-assoziierter viraler vektor zur exon- überspringung in einem für ein protein mit überflüssiger domäne kodierenden gen - Google Patents

Adeno-assoziierter viraler vektor zur exon- überspringung in einem für ein protein mit überflüssiger domäne kodierenden gen

Info

Publication number
ATE429252T1
ATE429252T1 AT05797742T AT05797742T ATE429252T1 AT E429252 T1 ATE429252 T1 AT E429252T1 AT 05797742 T AT05797742 T AT 05797742T AT 05797742 T AT05797742 T AT 05797742T AT E429252 T1 ATE429252 T1 AT E429252T1
Authority
AT
Austria
Prior art keywords
adeno
sequence
associated viral
gene encoding
viral vector
Prior art date
Application number
AT05797742T
Other languages
English (en)
Inventor
Luis Garcia
Original Assignee
Genethon
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genethon, Centre Nat Rech Scient filed Critical Genethon
Application granted granted Critical
Publication of ATE429252T1 publication Critical patent/ATE429252T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT05797742T 2004-08-17 2005-08-02 Adeno-assoziierter viraler vektor zur exon- überspringung in einem für ein protein mit überflüssiger domäne kodierenden gen ATE429252T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0451861A FR2874384B1 (fr) 2004-08-17 2004-08-17 Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
PCT/FR2005/050642 WO2006021724A2 (fr) 2004-08-17 2005-08-02 Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables

Publications (1)

Publication Number Publication Date
ATE429252T1 true ATE429252T1 (de) 2009-05-15

Family

ID=34948645

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05797742T ATE429252T1 (de) 2004-08-17 2005-08-02 Adeno-assoziierter viraler vektor zur exon- überspringung in einem für ein protein mit überflüssiger domäne kodierenden gen

Country Status (12)

Country Link
US (2) US20120077860A1 (de)
EP (2) EP1778297B1 (de)
JP (1) JP4885136B2 (de)
AT (1) ATE429252T1 (de)
CA (1) CA2576462C (de)
DE (1) DE602005014114D1 (de)
DK (1) DK1778297T3 (de)
ES (1) ES2324948T3 (de)
FR (1) FR2874384B1 (de)
PL (1) PL1778297T3 (de)
PT (1) PT1778297E (de)
WO (1) WO2006021724A2 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2933332A1 (de) 2004-06-28 2015-10-21 The University Of Western Australia Antisense-oligonukleotide zur induktion von exon-skipping sowie verfahren zur verwendung davon
EP2152873A2 (de) * 2007-03-16 2010-02-17 Biorigen S.r.l Technologie zur regulierung der genexpression und nichtkodierende rna für diagnose und therapie
BR122020021379B1 (pt) 2008-10-24 2021-05-11 Sarepta Therapeutics, Inc. oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular
WO2010093784A2 (en) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
CA2758189C (en) * 2009-04-10 2020-12-29 Association Institut De Myologie Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
TR201816523T4 (tr) 2009-11-12 2018-11-21 Univ Western Australia Patolojilerin tedavisine yönelik antisens moleküller ve yöntemler.
EP2524037B1 (de) 2010-01-12 2018-05-16 The University Of North Carolina At Chapel Hill Restriktive umgekehrte endverstärkungen für virusvektoren
US9080170B2 (en) * 2010-03-17 2015-07-14 Association Institut De Myologie Modified U7 snRNAs for treatment of neuromuscular diseases
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
WO2012109570A1 (en) 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
EP2500434A1 (de) 2011-03-12 2012-09-19 Association Institut de Myologie Capsidfreie AAV-Vektoren, Zusammensetzungen und Verfahren zur Vektorherstellung und Genlieferung
CA2834729A1 (en) 2011-04-06 2012-10-11 Universite Pierre Et Marie Curie (Paris 6) A skeletal muscle-specific enhancer
MX374963B (es) 2011-04-29 2025-03-06 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos.
EP2900686B1 (de) 2012-09-28 2020-06-10 The University of North Carolina At Chapel Hill Gegen oligodendrozyten gerichtete aav-vektoren
CN110218727A (zh) 2013-03-14 2019-09-10 萨勒普塔医疗公司 用于治疗肌营养不良的外显子跳跃组合物
ES2926774T3 (es) 2013-03-15 2022-10-28 Univ North Carolina Chapel Hill Métodos y composiciones para vectores AAV de doble unión de glicano
WO2014143932A1 (en) 2013-03-15 2014-09-18 The University Of North Carolina At Chapel Hill Synthetic adeno-associated virus inverted terminal repeats
US20140329762A1 (en) 2013-03-15 2014-11-06 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
MX388221B (es) 2013-04-20 2025-03-19 Res Institute At Nationwide Children´S Hospital ADMINISTRACIÓN DE VIRUS ADENO-ASOCIADO RECOMBINANTE DE CONSTRUCCIONES DE POLINUCLÉOTIDOS U7snRNA DIRIGIDA AL EXÓN 2.
BR122020023215B1 (pt) 2013-05-03 2022-11-22 Selecta Biosciences, Inc Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico
EP3044315B1 (de) 2013-09-11 2019-02-20 Synthena AG Nukleinsäuren und verfahren zur behandlung von morbus pompe
KR102524543B1 (ko) 2014-06-10 2023-04-20 에라스무스 유니버시티 메디컬 센터 로테르담 폼페병의 치료에 유용한 안티센스 올리고뉴클레오티드
EP3174981B1 (de) 2014-07-31 2020-03-25 Association Institut de Myologie Behandlung von amyotropher lateralsklerose
CA2957661A1 (en) 2014-08-09 2016-02-18 Kevin FLANIGAN Methods and materials for activating an internal ribosome entry site in exon 5 of the dmd gene
JP7242180B2 (ja) 2014-09-07 2023-03-20 セレクタ バイオサイエンシーズ インコーポレーテッド 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物
EP4344741A3 (de) 2014-11-21 2024-08-28 The University of North Carolina at Chapel Hill Auf das zentrale nervensystem gerichtete aav-vektoren
US10907176B2 (en) 2015-01-14 2021-02-02 The University Of North Carolina At Chapel Hill Methods and compositions for targeted gene transfer
HK1248554A1 (zh) 2015-02-20 2018-10-19 Board Of Regents, The University Of Texas System 作为疫苗和载体的减毒衣原体的方法和组合物
US20180237775A1 (en) 2015-09-21 2018-08-23 Association Institut De Myologie Antisense oligonucleotides and uses thereof
ES2865487T3 (es) 2015-09-28 2021-10-15 Univ North Carolina Chapel Hill Métodos y composiciones para vectores virales que evaden los anticuerpos
FR3044926B1 (fr) 2015-12-09 2020-01-31 Genethon Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
JP7406783B2 (ja) 2015-12-14 2023-12-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル パルボウイルスベクターの高められた送達のための改変キャプシドタンパク質
JP2019513371A (ja) 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
MX2019008199A (es) 2017-01-06 2019-11-25 Avidity Biosciences Llc Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
ES3036482T3 (en) 2017-03-11 2025-09-19 Cartesian Therapeutics Inc Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
NZ756587A (en) 2017-03-15 2025-12-19 Univ North Carolina Chapel Hill Polyploid adeno-associated virus vectors and methods of making and using the same
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
EP3759218A4 (de) 2018-02-28 2021-12-08 The University of North Carolina at Chapel Hill Verfahren und zusammensetzungen für antikörperausweichende virusvektoren
AU2019247748A1 (en) 2018-04-03 2020-10-08 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
MX2020010465A (es) 2018-04-03 2021-01-08 Vectores de virus para direccionamiento a tejidos oftalmicos.
EP3774852A1 (de) 2018-04-03 2021-02-17 Stridebio, Inc. Antikörpermeidende virale vektoren
AU2019287468B2 (en) 2018-06-12 2024-10-10 The University Of North Carolina At Chapel Hill Synthetic liver-tropic adeno-associated virus capsids and uses thereof
EP3806868A4 (de) * 2018-06-13 2022-06-22 Sarepta Therapeutics, Inc. Exon-skipping-oligomere für muskeldystrophie
EP3810782A2 (de) 2018-06-22 2021-04-28 Asklepios Biopharmaceutical, Inc. Vektoren zur genfreisetzung, die in zellen persistieren
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
CA3108282A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
SG11202100928QA (en) 2018-08-02 2021-02-25 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
JP2021534755A (ja) * 2018-08-22 2021-12-16 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 筋強直性ジストロフィープロテインキナーゼの発現を抑制および／またはｄｍｐｋ遺伝子の３’非翻訳領域におけるトリヌクレオチドリピート伸長に干渉するための組換えウイルス産物および方法
AR118465A1 (es) 2019-03-21 2021-10-06 Stridebio Inc Vectores de virus adenoasociados recombinantes
EP4169535A1 (de) 2019-04-26 2023-04-26 The University of North Carolina at Chapel Hill Verfahren und zusammensetzungen für dualen glycanbindenden aav2,5-vektor
AU2020287627A1 (en) 2019-06-04 2021-11-18 Selecta Biosciences, Inc. Formulations and doses of PEGylated uricase
KR102452590B1 (ko) * 2019-08-01 2022-10-12 기초과학연구원 CRISPR/Cas9 매개 체세포 핵 이식에 의한 개 디스트로핀병증 모델 생성 및 이의 용도
US12611436B2 (en) 2019-10-17 2026-04-28 Sarepta Therapeutics, Inc. AAV transfer cassette
JP2022551739A (ja) 2019-10-17 2022-12-13 ストライドバイオ，インコーポレイテッド ニーマン・ピック病ｃ型の治療のためのアデノ随伴ウイルスベクター
WO2021089736A1 (en) 2019-11-06 2021-05-14 Association Institut De Myologie Combined therapy for muscular diseases
AU2021216593A1 (en) 2020-02-04 2022-08-25 Duke University Compositions and methods for circular RNA expression
BR112022020412A2 (pt) 2020-04-09 2023-05-02 Association Inst De Myologie Sequências antissenso para tratar esclerose lateral amiotrófica
JP2023524577A (ja) 2020-05-05 2023-06-12 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 改変アデノ随伴ウイルス５カプシドおよびその使用
WO2022026516A1 (en) * 2020-07-29 2022-02-03 The Board Of Regents Of The University Of Texas System Transgene cassettes, aav vectors, and aav viral vectors for expression of human codon-optimized cstb
AU2021328475A1 (en) 2020-08-19 2023-03-16 Sarepta Therapeutics, Inc. Adeno-associated virus vectors for treatment of Rett syndrome
AU2021345112A1 (en) 2020-09-15 2023-04-27 Research Institute At Nationwide Children's Hospital Aav-mediated homology-independent targeted integration gene editing for correction of diverse dmd mutations in patients with muscular dystrophy
CN116490514A (zh) 2020-10-28 2023-07-25 北卡罗来纳-查佩尔山大学 用于双重聚糖结合aav2.5载体的方法和组合物
WO2022093769A1 (en) 2020-10-28 2022-05-05 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
TW202242124A (zh) 2021-01-14 2022-11-01 美商史崔德生物公司 靶向ｔ細胞之ａａｖ載體
EP4277644A1 (de) 2021-01-15 2023-11-22 Outpace Bio, Inc. Kleinmolekülreguliertes genexpressionssystem
US20240254509A1 (en) 2021-03-04 2024-08-01 Research Institute At Nationwide Children's Hospital Products and methods for treatment of dystrophin-based myopathies using crispr-cas9 to correct dmd exon duplications
WO2022221529A1 (en) 2021-04-16 2022-10-20 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
AU2022262420A1 (en) 2021-04-23 2023-11-16 Research Institute At Nationwide Children's Hospital Products and methods for treating muscular dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
JP2024525608A (ja) 2021-07-09 2024-07-12 ダイン セラピューティクス，インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体および製剤
EP4119682A1 (de) 2021-07-13 2023-01-18 Genethon Verfahren zur bestimmung der natur von dna-verunreinigungen in viruspartikeln
AU2022337146A1 (en) * 2021-09-03 2024-03-14 Tacit Therapeutics, Inc. Rna editing via recruitment of spliceosome components
EP4215614A1 (de) 2022-01-24 2023-07-26 Dynacure Kombinationstherapie für dystrophin-verwandte krankheiten
TW202342759A (zh) 2022-02-04 2023-11-01 美商史崔德生物公司 重組腺相關病毒載體及其使用方法
AU2023228712A1 (en) 2022-03-04 2024-10-17 Regeneron Pharmaceuticals, Inc. Compositions and methods comprising engineered small nuclear rna (snrna)
EP4603585A1 (de) * 2022-10-11 2025-08-20 Guangzhou Reforgene Medicine Co., Ltd. Snra-nukleinsäuremolekül und anwendung davon
WO2024124019A2 (en) 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Aav vectors targeting hematopoietic stem cells
WO2025079025A1 (en) 2023-10-13 2025-04-17 Takeda Pharmaceutical Company Limited Ides-rapamycin conjugate in aav gene therapy
WO2025179121A1 (en) 2024-02-21 2025-08-28 Research Institute At Nationwide Children's Hospital Exon 17-targeted nucleic acids, compositions, and methods for treatment of dystrophin-based myopathies
WO2026080823A1 (en) 2024-10-10 2026-04-16 Research Institute At Nationwide Children's Hospital Methods for diagnosing and treating muscular dystrophy diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000325085A (ja) 1999-05-21 2000-11-28 Masafumi Matsuo デュシェンヌ型筋ジストロフィー治療剤
CA2379166C (en) * 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
US7638120B2 (en) * 2000-03-14 2009-12-29 Thomas Jefferson University High transgene expression of a pseudotyped adeno-associated virus type
US6653467B1 (en) * 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
US6727355B2 (en) 2000-08-25 2004-04-27 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of Duchenne muscular dystrophy
EP1191097A1 (de) * 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induktion von "exon-skipping" in eukaryotischen Zellen
CN1620508A (zh) * 2001-12-21 2005-05-25 牛津生物医学（英国）有限公司 转基因生物
ITRM20020253A1 (it) 2002-05-08 2003-11-10 Univ Roma Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche.
AU2003225410A1 (en) * 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure

Also Published As

Publication number Publication date
WO2006021724A2 (fr) 2006-03-02
WO2006021724A3 (fr) 2006-08-31
US20130072541A1 (en) 2013-03-21
FR2874384A1 (fr) 2006-02-24
DE602005014114D1 (de) 2009-06-04
FR2874384B1 (fr) 2010-07-30
PT1778297E (pt) 2009-07-23
ES2324948T3 (es) 2009-08-20
CA2576462C (fr) 2013-03-12
CA2576462A1 (fr) 2006-03-02
US20120077860A1 (en) 2012-03-29
EP1778297B1 (de) 2009-04-22
JP2008509695A (ja) 2008-04-03
EP2014309A1 (de) 2009-01-14
JP4885136B2 (ja) 2012-02-29
EP1778297A2 (de) 2007-05-02
PL1778297T3 (pl) 2009-10-30
DK1778297T3 (da) 2009-07-27

Similar Documents

Publication Publication Date Title
ATE429252T1 (de) Adeno-assoziierter viraler vektor zur exon- überspringung in einem für ein protein mit überflüssiger domäne kodierenden gen
ZA202101938B (en) Bcma chimeric antigen receptor based on single domain antibody and use thereof
ES2528133T3 (es) Péptidos y composiciones para prevención de la adhesión celular, y métodos para utilizar los mismos
GEP20125594B (en) Sclerostin binding agents
DE60318391D1 (de) Bakteriophagen-lysin
ATE444342T1 (de) Poliersystem mit hochverzweigtem polymer
DE602004027538D1 (de) Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
ATE326984T1 (de) Verfahren zur verbindung von molekularen substanzen
CY1116649T1 (el) Τεχνητη dna αλληλουχια με βελτιστοποιημενη λειτουργια οδηγου σε 5' (5-utr) για βελτιωμενη εκφραση ετερολογων πρωτεϊνων σε φυτα
ATE540115T1 (de) Nukleinsäurekonstruktsysteme mit fähigkeit zur diagnose oder behandlung eines zellzustands
EP1859046A4 (de) Expressionsvektor für tierische zelle mit wenigstens einer kopie von mar-dna-sequenzen am 3'-ende des transkriptionsterminationsbereichs eines gens sowie verfahren zur expression eines fremdgens unter verwendung des vektors
DE50110597D1 (de) L-Aminosäure-Oxidase aus Rhodococcus-Arten
ATE529441T1 (de) Expression von proteinen in e.coli
WO2003020887A3 (en) Gene identification
WO2002066636A3 (en) T cell receptor variants expressed in mesenchymal cells and uses thereof
CY1107186T1 (el) Προαγωγος πολυμερασης i rna κοτοπουλου και η χρηση αυτου
WO2006054297A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
ATE428783T1 (de) Expressionssystem für sirna
PE20000177A1 (es) GEN dtsR TERMOSENSIBLE
DK1625152T3 (da) Peptider, som modulerer sktiviteten af Engrailed-transskriptionsfaktoren
EA200800098A1 (ru) Экспрессионный вектор и способ продуцирования высоких уровней белков
DE502005007057D1 (de) Verfahren zur herstellung von (s)-butan-2-ol
ATE421971T1 (de) Isostere transformation
EP1801211A4 (de) Hla bindendes peptid, dieses codierendes dna-fragment und rekombinanter vektor
ES2271040T3 (es) Factores especificos de hifa procedentes de candida albicans.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1778297

Country of ref document: EP

EEIH Change in the person of patent owner